Granted Patent
B2
US 12,698,487 · App. 18/063,263 · Granted Aug 4, 2026
Soluble ENPP1 proteins and uses thereof
Inventors:
Zhiliang Cheng (Boston, MA); Demetrios Braddock (Guilford, CT); Paul Stabach (New Haven, CT); Steven Jungles (Key West, FL)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
In certain aspects, the present invention provides novel soluble ENPP1 or ENPP3 polypeptides, as well as compositions and methods for using those variants to treat an indication associated an ENPP1 or ENPP3 deficiency. The compositions and methods provided herein are useful in treating diseases associated with an ENPP1 or ENPP3 deficiency such as pathological calcification or pathological ossification.
Claims (9)
1 . A soluble ectonucleotide pyrophosphatase/phosphodiesterase (ENPP1) polypeptide that lacks both Somatomedin B (SMB) domain 1 and SMB domain 2 of ENPP1, and wherein the soluble ENPP1 polypeptide is at least 90% identical to the amino acid sequence of SEQ ID NO: 121 and the catalytic domain of the ENPP1 portion of the soluble ENPP1 polypeptide comprises a 1332T substitution and the Fc domain comprises a triple mutation (M252Y, S254T, T256E).
2 . The soluble ENPP1 polypeptide of claim 1 , wherein the soluble ENPP1 polypeptide comprises the amino acid sequence of SEQ ID NO: 121.
3 . The soluble ENPP1 polypeptide of claim 1 , wherein the polypeptide has reduced ability to homodimerize as compared to the corresponding wild-type soluble ENPP1; and/or
wherein the polypeptide has reduced affinity for the human insulin receptor (IR) as compared to the corresponding wild-type soluble ENPP1 polypeptide.
4 . The soluble ENPP1 polypeptide of claim 1 , wherein the ENPP1 polypeptide demonstrates greater proteolytic resistance to a protease than the corresponding wild-type soluble ENPP1 polypeptide.
5 . The soluble ENPP1 polypeptide of claim 1 , wherein the greater proteolytic resistance of the ENPP1 polypeptide provides a homogenous composition with protein purity increased by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 175%, 200%, 225%, 250%, 275%, or 300% as compared to a corresponding wild-type soluble ENPP1 polypeptide; and/or
wherein the greater proteolytic resistance of the ENPP1 polypeptide decreases protein cleavage by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 175%, 200%, 225%, 250%, 275%, or 300% as compared to the corresponding wild-type soluble ENPP1 polypeptide; and/or
wherein the protease is trypsin or trypsin-like proteases.
6 . The soluble ENPP1 polypeptide according to claim 1 , wherein the soluble ENPP1 polypeptide further comprises a heterologous moiety and wherein the heterologous moiety is selected from the group consisting of a glycosylated amino acid, a PEGylated amino acid, a farnesylated amino acid, an acetylated amino acid, a biotinylated amino acid, and a lipid moiety.
Assignments (4)
SECURITY INTEREST
Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 25, 2025
From: INOZYME PHARMA, INC.
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 073707/0488 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 4, 2024
From: CHENG, ZHILIANG; JUNGLES, STEVEN
To: INOZYME PHARMA, INC.
Reel/Frame 067009/0515 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 4, 2024
From: BRADDOCK, DEMETRIOS; STABACH, PAUL
To: YALE UNIVERSITY
Reel/Frame 067009/0554 →
Continuity (3)
Continuation
PCTUS2021036494
· Jun 8, 2021
Provisional Application
63036833
· Jun 9, 2020
Related Publication
20230313158A1
· Oct 5, 2023
References Cited (309)
US 4751180A
· Cousens et al.
· 1988
[cited by applicant]
US 4935233A
· Bell et al.
· 1990
[cited by applicant]
US 5418618A
· Kagawa et al.
· 1995
[cited by applicant]
US 5428130A
· Capon et al.
· 1995
[cited by applicant]
US 5804413A
· DeLuca
· 1998
[cited by applicant]
US 5808656A
· Goldmann
· 1998
[cited by applicant]
US 5837532A
· Preston et al.
· 1998
[cited by applicant]
US 5846782A
· Wickham et al.
· 1998
[cited by applicant]
US 5968508A
· Goldfine et al.
· 1999
[cited by applicant]
US 6001650A
· Colosi
· 1999
[cited by applicant]
US 6043056A
· Yue et al.
· 2000
[cited by applicant]
US 6156303A
· Russell et al.
· 2000
[cited by applicant]
US 6358923B1
· Yue et al.
· 2002
[cited by applicant]
US 6455495B1
· Orgel et al.
· 2002
[cited by applicant]
US 6498617B1
· Shida et al.
· 2002
[cited by applicant]
US 6596535B1
· Carter
· 2003
[cited by applicant]
US 6730822B1
· Ivarie et al.
· 2004
[cited by applicant]
US 6825396B2
· MacArthur
· 2004
[cited by applicant]
US 6875588B2
· Harvey et al.
· 2005
[cited by applicant]
US 7125717B2
· Carter
· 2006
[cited by applicant]
US 7294507B2
· Harvey et al.
· 2007
[cited by applicant]
US 7312374B2
· Rapp et al.
· 2007
[cited by applicant]
US 7318919B2
· Gregory et al.
· 2008
[cited by applicant]
US 7323542B2
· Balian
· 2008
[cited by applicant]
US 7456683B2
· Takano et al.
· 2008
[cited by applicant]
US 7507873B2
· Harvey et al.
· 2009
[cited by applicant]
US 7521591B2
· Ivarie et al.
· 2009
[cited by applicant]
US 7531167B2
· Glorioso et al.
· 2009
[cited by applicant]
US 7534929B2
· Ivarie et al.
· 2009
[cited by applicant]
US 7858297B2
· Girard et al.
· 2010
[cited by applicant]
US 7888372B2
· Millan et al.
· 2011
[cited by applicant]
US 7902151B2
· Gorczynski et al.
· 2011
[cited by applicant]
US 7960529B2
· Crine et al.
· 2011
[cited by applicant]
US 8519214B2
· Ivarie et al.
· 2013
[cited by applicant]
US 8846603B2
· Quinn et al.
· 2014
[cited by applicant]
US 9540621B2
· Quinn et al.
· 2017
[cited by applicant]
US 9642869B2
· Reddy et al.
· 2017
[cited by applicant]
US 9642896B1
· Braddock et al.
· 2017
[cited by applicant]
US 9744219B2
· Braddock et al.
· 2017
[cited by applicant]
US 9867870B2
· Braddock et al.
· 2018
[cited by applicant]
US 9913881B2
· Braddock et al.
· 2018
[cited by applicant]
US 20010051065A1
· Togami
· 2001
[cited by applicant]
US 20020108132A1
· Rapp
· 2002
[cited by applicant]
US 20040224893A1
· Wang et al.
· 2004
[cited by applicant]
US 20060074255A1
· Takayama et al.
· 2006
[cited by applicant]
US 20070015145A1
· Woolf et al.
· 2007
[cited by applicant]
US 20080273206A1
· Genge et al.
· 2008
[cited by applicant]
US 20090180989A1
· Harvey
· 2009
[cited by applicant]
US 20100184672A1
· McCarty et al.
· 2010
[cited by applicant]
US 20100203076A1
· Fotin-Mleczek et al.
· 2010
[cited by applicant]
US 20120009592A1
· Froguel et al.
· 2012
[cited by applicant]
US 20140154774A1
· Quinn et al.
· 2014
[cited by applicant]
US 20150024460A1
· Quinn et al.
· 2015
[cited by applicant]
US 20160184458A1
· Heartlein
· 2016
[cited by applicant]
US 20170145393A1
· Quinn et al.
· 2017
[cited by applicant]
US 20180371434A1
· Braddock et al.
· 2018
[cited by applicant]
DE 20121960U1
· 2004
[cited by applicant]
EP 2368999B1
· 2014
[cited by applicant]
EP 3298140A1
· 2018
[cited by applicant]
JP H04292169A
· 1992
[cited by applicant]
JP 2008188015A
· 2008
[cited by applicant]
JP 2014509851A
· 2014
[cited by applicant]
JP 2014509617A
· 2014
[cited by applicant]
JP 2016530899A
· 2016
[cited by applicant]
JP 2018511346A
· 2018
[cited by applicant]
JP 2018527882A
· 2018
[cited by applicant]
JP 6894664B2
· 2021
[cited by applicant]
RU 2272841C2
· 2006
[cited by applicant]
RU 2013142583A
· 2015
[cited by applicant]
WO 9102788A1
· 1991
[cited by applicant]
WO 9604394A1
· 1996
[cited by applicant]
WO 9815637A1
· 1998
[cited by applicant]
WO 9906583A1
· 1999
[cited by applicant]
WO 1999019495A1
· 1999
[cited by applicant]
WO 2000032217A1
· 2000
[cited by applicant]
WO 0239994A2
· 2002
[cited by applicant]
WO 2002092020A2
· 2002
[cited by applicant]
WO 03040340A2
· 2003
[cited by applicant]
WO 2006039480A2
· 2006
[cited by applicant]
WO 2006059113A2
· 2006
[cited by applicant]
WO 2006135925A2
· 2006
[cited by applicant]
WO 2006135935A1
· 2006
[cited by applicant]
WO 2008065225A2
· 2008
[cited by applicant]
WO 2008105911A2
· 2008
[cited by applicant]
WO 2011113027A2
· 2011
[cited by applicant]
WO 2012125182A1
· 2012
[cited by applicant]
WO 2014126965A2
· 2014
[cited by applicant]
WO 2016100803A2
· 2016
[cited by applicant]
WO 2016187408A1
· 2016
[cited by applicant]
WO 2017087936A1
· 2017
[cited by applicant]
WO 2017191274A2
· 2017
[cited by applicant]
WO 2017218786A1
· 2017
[cited by applicant]
WO 2018027024A1
· 2018
[cited by applicant]
WO 2018157165A1
· 2018
[cited by applicant]
WO 2019067502A1
· 2019
[cited by applicant]
WO 2019217373A1
· 2019
[cited by applicant]
WO 2020047520A1
· 2020
[cited by applicant]
WO 2020150716A1
· 2020
[cited by applicant]
WO WO2020206302A1
· 2020
[cited by examiner]
WO 2021252549A1
· 2021
[cited by applicant]
WO 2022076848A1
· 2022
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2021/036494, issued Dec. 13, 2022, 18 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/036494, mailed Feb. 12, 2021, 28 pages.
[cited by applicant]
Jansen , et al., “ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release”, Proc Natl Acad Sci U S A. 110(50), 2013, 20206-20211.
[cited by applicant]
Jansen , et al., “ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor Inorganic pyrophosphate in the systemic circulation-brief report”, Arterioscler Thromb Vasc Biol. 34(9), 201…
[cited by applicant]
Jansen , et al., “Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D”, J Cell Sci. 118(Pt 14), 2005, 3081-3089.
[cited by applicant]
Jansen , et al., “Structure of NPP1, an ectonucleotide pyrophosphatase/phosphodiesterase involved in tissue calcification”, Structure. 20(11), 2012, 1948-1959.
[cited by applicant]
Jia, et al., “A novel model of adenine-induced tubulointerstitial nephropathy in mice”, BMC Nephrology 2013, 14: 116.
[cited by applicant]
Jiang, et al., “Aberrant Mineralization of Connective Tissues in a Mouse Model of Pseudoxanthoma Elasticum: Systemic and Local Regulatory Factors”, Journal of Investigative Dermatology 2007, 127(6): 1392-1402.
[cited by applicant]
Jin-Hua , et al., “Molecular Cloning and Chromosomal Localization of PD-Iβ (PDNP3), a New Member of the Human Phosphodiesterase I Genes,” Genomics 45, 1997, 412-415.
[cited by applicant]
Johnson , et al., “Matrix vesicle plasma cell membrane glycoprotein-1 regulates mineralization by murine osteoblastic MC3T3 cells”, J Bone Miner Res. 14(6), Jun. 1999, 883-892.
[cited by applicant]
Johnson, et al. “The nucleoside triphosphate pyrophosphohydrolase isozyme PC-1 directly promotes cartilage calcification through chondrocyte apoptosis and increased calcium precipitation by mineralizing vesicles.” The J…
[cited by applicant]
Johnson, et al., “Chondrogenesis Mediated by PPi Depletion Promotes Spontaneous Aortic Calcification in NPP1-/-mice” Arteriosclerosis Thrombosis, and Vascular Biology, 25: 686-691 (2005).
[cited by applicant]
Johnson, et al., “Differential mechanisms of inorganic pyrophosphate production by plasma cell membrane glycoprotein-1 and B10 in chondrocytes”, Arthritis Rheum. 42(9) , 1999 , 1986-1997.
[cited by applicant]
Johnson, et al., “Kabat database and its applications: 30 years after the first variability plot,” Nucleic Acids Res. 28(1), Jan. 2000, 214-218.
[cited by applicant]
Johnson, et al., “Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression”, J Bone Miner Res. 18(6) , 2003 , 994-1004.
[cited by applicant]
Kashioulis et al. 2018; Adenine-diced chronic renal failure in rates: A model of chronic renocardiac syndrome with left ventricular diastolic dysfunction by preserved ejection fraction. Kidney & Blood Pressure Research.…
[cited by applicant]
Kato , et al., “Crystal structure of Enpp1, an extracellular glycoprotein involved in bone mineralization and insulin signaling”, Proc Natl Arad Sci U S A. 109(42), Oct. 2012, 16876-16881.
[cited by applicant]
Khan, et al., “Experimental Induction of Calcium Oxalate Nephrolithiasis in Mice”, The Journal of Urology 2010, vol. 184, Issue 3, 1189-1196.
[cited by applicant]
Khan, et al., “Ultrastrucural Investigation of Crystal deposits in Npt2a knockout mice: Are they similar to Human Randall's plaques?” J Urol. 2011, 186(3): 1107-1113.
[cited by applicant]
Khan, T. et al., “ENPP1 enzyme replacement therapy improves blood pressure and cardiovascular function in a mouse model of generalized arterial calcification of infancy,” Disease Models & Mechanisms, 11(10):dmm035691, 1…
[cited by applicant]
Kober, et al., “Optimized Signal Peptides for the Development of High Expressing CHO Cell Lines”, Biotechnology and Bioengineering, 2013, 110(4): 1164-1173.
[cited by applicant]
Lee , et al., “Cloning' chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma ;ells”, Biochem Biophys Res Commun. 218(3, 1996, 714-719.
[cited by applicant]
Levy-Litan, et al., “Autosomal-Recessive Hypophosphatemic Rickets Is Associated with an Inactivation Mutation in the ENPP1 Gene”, The American Journal of Human Genetics 86, 273-278, 2010.
[cited by applicant]
Li , et al., “Inhibition of Tissue-Nonspecific Alkaline Phosphatase Attenuates Ectopic Mineralization in the Abcc6 -/- Mouse Model of PXE but Not in the Enpp1 Mutant Mouse Models of GACI”, J Invest Dermatol. 139(2), Feb…
[cited by applicant]
Li , et al., “Response of Npt2a knockout mice to dietary calcium and phosphorus”, PLoS One. 12(4), 2017, e0176232.
[cited by applicant]
Li, et al. “Serum phosphate concentration and incidence of stroke: a systemic review and meta-analysis.” Neurological sciences 35.12 (2014): 1877-1882.
[cited by applicant]
Li, et al., “Mutant Enpp1 asj mice as a model for generalized arterial calcification of infancy”, Disease Models & Mechanisms 6, 1227-1235 (2013).
[cited by applicant]
Li, Q., et al., “Spontaneous asj-2J mutant mouse as a model for generalized arterial calcification of infancy: a large deletion/insertion mutation in the Enpp1 gene,” PLoS ONE, vol. 9, No. 12, Dec. 5, 2014, pp. e113542.
[cited by applicant]
Liang, et al., “Survey of the Enthesopathy of X-Linked Hypophosphatemia and Its Characterization in Hyp Mice”, Calcif. Tissue Int. 2009, 85(3): 235-46.
[cited by applicant]
Lieben , et al., “Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization”, J Clin Invest. 122(5), 2012, 1803-1805.
[cited by applicant]
Lock, et al., “Characterization of a Recombinant Adeno-Associated Virus Type 2 Reference Standard Material”, Human Gene Therapy 21: 1273-1285 (2010).
[cited by applicant]
Lomashvili, et al., “Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin,” Journal of American Society of Nephrology, 1392-1401, Mar. 4, 2004.
[cited by applicant]
Lust, et al., “A rapid, enzymatic assay for measurement of inorganic pyrophosphate in biological samples”, Clinica Chimica Acta 66, 1976, 241-249.
[cited by applicant]
MacKenzie et al. 2012; New insights into NPP1 function: Lessons from clinical and animal studies. Bone. 51:961-968.
[cited by applicant]
MacKenzie, et al., “Altered Bone Development and an Increase in FGF-23 Expression in Enpp1 -/- Mice”, PLoS one 2012, 7(2): e32177.
[cited by applicant]
Millán , et al., “Enzyme replacement therapy for murine hypophosphatasia”, J Bone Miner Res. 23(6), Jun. 2008, 777-787.
[cited by applicant]
Morrison, et al., “Experimentally Induced Chronic Renal Insufficiency in the Rat”, Laboratory Investigation vol. 11, 1962, 321-332.
[cited by applicant]
Murphy, et al., “Synthesis and in vitro hydroxyapatite binding of peptides conjugated to calcium-binding moieties,” Biomacromolecules, 8:2237-2243 (2007).
[cited by applicant]
Mus musculus domesticus ecto-nucleotide pyrophosphatase/phosphodiesterase-1 mRNA, complete cds, GenBank J027002, Aug. 12, 2020 searched.
[cited by applicant]
Nagase, et al., Uniprot Submission Accession No. Q9Y6X5 (online at <www.uniprot.org/uniprot/Q9Y6X5.txt?uersion=66>), 2011.
[cited by applicant]
Nakamura, et al., “Association of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL)”, Human Genetics, 1999, 104(6): 492-497.
[cited by applicant]
Nakanishi, et al. “Development and therapeutic application of transposon-based vectors.” Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan 129.12 (2009): 1433-1443.
[cited by applicant]
Nishioka, et al., “Enhancement of drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide,” Molecular Genetics and Metabolism vol. 88, Issue 3, Jul. 20…
[cited by applicant]
Nitschke, Y et al., “Npp1 promotes atherosclerosis in ApoE knockout mice,” Journal of Cellular and Molecular Medicine, vol. 15(11):2273-2283 (2011).
[cited by applicant]
Nitschke, Y., et al., “ENPP1-Fc prevents neointima formation in generalized arterial calcification of infancy through the generation of AMP,” Experimental and Molecular Medicine, Oct. 2018, vol. 50, No. 10, Article 139,…
[cited by applicant]
Nitschke, Y., et al., “Generalized arterial calcification of infancy and pseudoxanthoma elasticum: two sides of the same coin,” Frontiers in Genetics 2012, vol. 3 302, 3 pages.
[cited by applicant]
O'Neill, et al., “Treatment with pyrophosphate inhibits uremic vascular calcification,” International Society of Nephrology, 512-517, Mar. 2011.
[cited by applicant]
Oganesyan, et al., “Structural characterization of a human Fc fragment engineered for extended serum half-life,” Molecular Immunology vol. 46, No. 8-9, 2009, pp. 1750-1755.
[cited by applicant]
Ogilvie, et al., Identification and partial characterization of an adenosine(5′)tetraphospho(5′)adenosine hydrolase on intact bovine aortic endothelial cells, Biochem J. 259(1) ,1989 ,97-103.
[cited by applicant]
Okawa , et al., “Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine”, Nat Genet. 19(3), Jul. 1998, 271-273.
[cited by applicant]
Chen, et al., “Fusion Protein Linkers: Property, Design and Functionality”, Adv Drug Deliv Rev., 65 (10), pp. 1357-1369, Oct. 15, 2013 (Oct. 15, 2013).
[cited by applicant]
Ferreira, C., et al., “Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI),” Genet Med. Feb. 2021;23(2):396-407.
[cited by applicant]
Genbank Accession No. XP _006144365.1, Retrieved from the Internet «https://www.ncbi.nlm.nih.gov/protein/XP_006144365.1? report=genbank&log$=protalign&blast_rank=92&RI D=X9E 1 SC3Z016», Retrieved on Feb. 20, 2024.
[cited by applicant]
Goding , et al., “Ecto-phosphodiesterase/pyrophosphatase of lymphocytes and non-lymphoid cells: Structure and function of the PC-1 family,” Immunological Reviews, 161: 11-26 (1998).
[cited by applicant]
Kassim, et al. (Clinical Advances in Hematology & Oncology vol. 14, Issue 5 May 2016 pp. 307-309).
[cited by applicant]
Koike, et al., “The N-terminal hydrophobic sequence of autotaxin (ENPP2) functions as a signal peptide”, Genes to Cells, 11 (2), pp. 133-142, Jan. 4, 2006.
[cited by applicant]
Luthje, et al., Diadenosine triphosphate (Ap3A) mediates human platelet aggregation by liberation of ADP, Biochem Biophys Res Commun. 118(3) , 1984 , 704-709.
[cited by applicant]
NCBI Accession No. NM_006208, Mar. 2001.
[cited by applicant]
Nitschke, Y., et al., “Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6,” Am J Hum Genet. Jan. 13, 2012;90(1):25-39.
[cited by applicant]
Nitschke, Y., et al., “Inherited Arterial Calcification Syndromes: Etiologies and Treatment Concepts,” Curr Osteoporos Rep. Aug. 2017;15(4):255-270.
[cited by applicant]
Okada, et al., “Scalable purification of adeno-associated virus serotype 1 (AAV1) and AAV8 vectors, using dual ion-exchange adsorptive membranes”, Human Gene Therapy vol. 20, 2009, 1013-1021.
[cited by applicant]
Printout of bleeding disorders from the American Society of Hematology, downloaded Sep. 11, 2017 from world wide web.iematology.org/Patients?Bleeding.aspx, 5 pages.
[cited by applicant]
Yin, et al. “Glycoengineering of Chinese hamster ovary cells for enhanced erythropoietin N-glycan branching and sialylation.” Biotechnology and bioengineering 112.11 (2015): 2343-2351.
[cited by applicant]
Otero, J., et al., “Severe Skeletal Toxicity From Protracted Etidronate Therapy for Generalized Arterial Calcification of Infancy,” Journal of Bone and Mineral Research, 2013, vol. 28, No. 2, pp. 419-430.
[cited by applicant]
Papadakis, et al., “Promoters and Control Elements: Designing Expression Cassettes for Gene Therapy”, Current Gene Therapy, 2004, 4, 89-113.
[cited by applicant]
Parati et al. 2016; “Hypertension in chronic kidney disease Part 1.” Hypertension. 67(6): 1093-1101.
[cited by applicant]
Parfitt, et al., “Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee”, Journal of Bone and Mineral Research vol. 2, 1987, 595-610.
[cited by applicant]
Pharmacokinetic Control of Biopharmaceuticals, Journal of Pharmaceutical Science and Technology, Japan, 2014, 27-32 (Partial Translation).
[cited by applicant]
Rashdan, N.A. et al., “New perspectives on rare connective tissue calcifying diseases,” Current Opinion in Pharmacology, 28:14-23 (2016).
[cited by applicant]
Rath, et al. “Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics.” Critical reviews in biotechnology 35.2 (2015): 235-254.
[cited by applicant]
Ratkalkar, et al., “Mechanisms of Stone Formation”, Clin Rev Bone Miner Metab. 9(3-4), 2011, 187-197.
[cited by applicant]
Rezg, R., et al., “Inhibitors of Vascular Calcification as Potential Therapeutic Targets”, J. Nephrol, Jul.-Aug. (2011), vol. 24, No. 4: pp. 416-427.
[cited by applicant]
Robbie, et al. “A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an axtended half-life in healthy adults.” Antimicrobial agents and chemotherapy 57.12 (2013): 6147-6153.
[cited by applicant]
Rogers, et al. “Recombinant human serum albumin fusion proteins and novel applications in drug delivery and therapy.” Current pharmaceutical design 21.14 (2015): 1899-1907. Abstract.
[cited by applicant]
Rosenfeld, et al., “Adenovirus-Mediated Transfer of a Recombinant Alpha 1-Antitrypsin Gene to the Lung Epithelium in Vivo”, Science vol. 252, 1991, 431-434.
[cited by applicant]
Rosenfeld, et al., “In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium”, 1992, Cell 68: 143-155.
[cited by applicant]
Rutsch, et al., “Mutations in ENPP1 are associated with ‘idiopathic’ infantile arterial calcification,” Nature Genetics, 34: (4) 379-381 (2003).
[cited by applicant]
Rutsch, F. et al., “Genetics in Arterial Calcification Pieces of a Puzzle and Cogs in a Wheel,” Circulation Research, vol. 109:578-592 (2011).
[cited by applicant]
Rutsch, F. et al., “Hypophosphatemia, Hyperphosphaturia, and Bisphosphonate Treatment Are Associated With Survival Beyond Infancy in Generalized Arterial Calcification of Infancy,” Circ Cardiovasc Genet., vol. 1(2): 133…
[cited by applicant]
Sahota, et al., “Novel cystine ester mimics for the treatment of cystinuria-induced urolithiasis in a knockout mouse model”, Urology 2014, 84(5): 1249 e9-15.
[cited by applicant]
Sakagami, et al., Biochemical and molecular characterization of a novel choline-specific glycerophosphodiester phosphodiesterase belonging to the nucleotide pyrophosphatase/phosphodiesterase family, J Biol Chem. 280 ,24…
[cited by applicant]
Saunders, et al., “Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion” Mol. Cancer Ther. 7(10): 3352-62 (2008).
[cited by applicant]
Saunders, et al., Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution, J Biol Chem. 286(34), 2011,30130-30141.
[cited by applicant]
Sayer “Progress in understanding the genetics of calcium-containing nephrolithiasis.” Journal of the American Society of Nephrology 28.3 (2017): 748-759.
[cited by applicant]
Schetter, et al., “Nucleoporins NPP-1, NPP-3, NPP-4, NPP-11 and NPP-13 are required for proper spindle orientation in C. elegans”, Dev Biol. 289(2), Jan. 15, 2006, 360-371.
[cited by applicant]
Schmidt, “Fusion Proteins as Biopharmaceuticals—Applications and Challenges,” Current Opinion in Drug Discovery & Development, 12:1-12 (2009).
[cited by applicant]
Schwartz, et al., “Clinical Evaluation of Live, Oral Types 1,2, and 5 Adenovirus Vaccines”, American Review of Respiratory Disease vol. 109, 1974, 233-238.
[cited by applicant]
Serrano, R. et al., “Mono-allelic and bi-allelic ENPP1 deficiency promote post-injury neointimal hyperplasia associated with increased C/EBP homologous protein expression”, Atherosclerosis, vol. 233 (2):493-502 (2014).
[cited by applicant]
Shankar , et al., “Progeria-A Brief Review”, International Journal of Pharma and Bio Sciences 2, 2010, 1-14.
[cited by applicant]
Shaw, G., et al., “Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells,” FASEB J. 16, 2002, 19 pages.
[cited by applicant]
Sheehan , et al., “Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes”, Am J Hematol. 88(7), 2013, 571-576.
[cited by applicant]
Shimamura, et al., “A Progressive Glomerulosclerosis Occuring in Partial Five-sixths Nephrectomized Rats”, Am. J. Pathol. 1975, 79(1): 95-106.
[cited by applicant]
Silcox , et al., “Measurement of inorganic pyrophosphate in biological fluids. Elevated levels in some patients with Ostecorthritis, pseudogout, acromegaly, and uremia”, J Clin Invest. 52(8), Aug. 1973, 1863-1870.
[cited by applicant]
Singer, M., et al., Genes and Genomes, “Mir”, Moscow, 1998, vol. 1, pp. 1-369, in Russian. English translation of relevant parts.
[cited by applicant]
Siu, S., et al., “Variable patterns of ectopic mineralization in Enpp1asj-2J mice, a model for generalized arterial calcification of infancy,” Oncotarget, 2016, vol. 7, No. 51, pp. 83837-83842.
[cited by applicant]
Stefan , et al., “NPP-type ectophosphodiesterases: unity in diversity.”, Trends Biochem Sci. 30(10), Oct. 2005, 542-550.
[cited by applicant]
Terkeltaub , “Physiologic and pathologic functions of the NPP nucleotide pyrophosphatase/phosphodiesterase family focusing on NPP1 in calcification.”, Purinergic Signal. 2(2), Jun. 2, 2006, 371-377.
[cited by applicant]
Tsai , et al., “The Ectoenzyme E-NPP3 Negatively Regulates ATP—Dependent Chronic Allergic Responses by basophils and Mast Cells”, Immunity 42, Feb. 2015, 279-293.
[cited by applicant]
UniProt Accession No. O14638, ENPP3 Human, Jan. 7, 2015 [online]. [Retrieved on Jan. 19, 2017]. Retrieved from the internet <URL: http://www.uniprot.org/uniprot/O14638.txt?version=133>.
[cited by applicant]
Uniprot, Accession No. P22413, 2009, www.uniprot.org. (Year: 2009).
[cited by applicant]
Van Meeteren , et al., “Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate”, J Biol Chem. 280(22), Jun. 2005, 21155-21161.
[cited by applicant]
Villa-Bellosta, et al., “Defective Extracellular Pyrophosphate Metabolism Promotes Vascular Calcification in a Mouse Model of Hutchinson-Gilfrd Progeria Syndrome That is Ameliorated on Pyrophosphate Treatment”, Circulat…
[cited by applicant]
Virag, et al., “ Producing Recombinant Adeno-Associated Virus in Foster Cells: Overcoming Production Limitations Using a Baculovirus-Insect Cell Expression Strategy”, Human Gene Therapy 20: 807-817 (2009).
[cited by applicant]
Vollmayer, et al., Hydrolysis of diadenosine polyphosphates by nucleotide pyrophosphatases/phosphodiesterases, Eur J Biochem. 270(14) ,2003 ,2971-2978.
[cited by applicant]
Wagner, et al., “Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1”, Proc. Natl. Acad. Sci. USA vol. 78, No. 3, 1981, 1441-1445.
[cited by applicant]
Wang, et al., “Pharmacokinetic and Biodistribution Studies of a Bone-targeting Drug Delivery System Based on N-(2-Hydroxypropyl)methacrylamide (HPMA) Copolymers,” Molecular Pharmaceutics 3(6): 717-725 (2006).
[cited by applicant]
Ware, et al., “Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death”, Development 121, 1283-1299 (1995).
[cited by applicant]
Whisstock, et al., “Prediction of proteinfunction fromprotein sequence and structure”, Quarterly Reviews of Biophysics 36, 3 (2003), pp., 2003, 307-340.
[cited by applicant]
Witkowski , et al., “Conversion of a Beta-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine With Glutamine”, Biochemistry 38(36), Sep. 1999, 11643-11650.
[cited by applicant]
Wu, et al., “Hyperuricemia and urate nephropathy in urate oxidase-deficient mice”, Proc. Natl. Acad. Sci. USA vol. 91, 742-746 (1994).
[cited by applicant]
Wu, et al., “Interstitial Calcinosis in Renal Papillae of Genetically Engineered Mouse Models: Relation to Randall's Plaques”, Urolithiasis 43, 65-76 (2015).
[cited by applicant]
Yamamoto, et al., “Identification of a Functional Promoter in the Long Terminal Repeat of Rous Sarcoma Virus”, Cell vol. 22, 1980, 787-797.
[cited by applicant]
Zee, et al., “α-Lipoic acid treatment prevents cystine urolithiasis in a mouse model of cystinuria”, Nat Med. 2017, 23(3): 288-290.
[cited by applicant]
Zettervall, S., et al., “Association of arterial calcification with chronic limb ischemia in patients with peripheral artery disease,” Journal of Vascular Surgery, Feb. 2018, vol. 67, No. 2, pp. 507-513.
[cited by applicant]
Zhang , et al., “The interaction of cationic polymers and their bisphosphonate derivatives with hydroxyapatite”, Macromol Biosci. 7(5), May 10, 2007, 656-670 (Abstract Only).
[cited by applicant]
Zhang, et al., “Adenovirus-Adeno-Associated Virus Hybrid for Large-Scale Recombinant Adeno-Associated Virus Production”, Human Gene Therapy 2009, vol. 20, No. 9, 922-929.
[cited by applicant]
Zhang, et al., Investigation of the role of ENPP1 and TNAP genes in chondrocalcinosis, Rheumatology, vol. 46, Issue 4, Apr. 2007, pp. 586-589.
[cited by applicant]
Japan Patent Office, Notice of Reasons for Refusal for Japanese Patent Application No. 2022-575745, dated May 21, 2025 with English translation, 10 pages.
[cited by applicant]
[No Author Listed] “Breeding Strategies for Maintaining Colonies of Laboratory Mice: A Jackson Laboratory Resource Manual”, 2007, 1-29.
[cited by applicant]
Agapov, et al., “Noncytopathic Sindbis virus RNA vectors for heterologous gene expression”, Proc. Natl. Acad. Sci. USA vol. 95, 1998, 12989-12994.
[cited by applicant]
Albright, et al., “ENPP1-Fc prevents mortality and vascular calcifications in rodent model of generalized arterial calcification of infancy”, Nat Commun. 6, 2015, 10006.
[cited by applicant]
Albright, et al., “Molecular basis of purinergic signal metabolism by ectonucleotide pyrophosphatase/phosphodiesterases 4 and 1 and implications in stroke”, J Biol Chem. 289(6) ,2014 , 3294-3306.
[cited by applicant]
Albright, et al., “NPP4 is a procoagulant enzyme on the surface of vascular endothelium”, Blood. 120(22) ,2012 , 4432-4440.
[cited by applicant]
Altschul, et al., “Basic Local Alignment Search Tool”, Journal of Molecular Biology, vol. 215, Issue 3, 1990, 403-410.
[cited by applicant]
Anonymous , “UPI000511D809”, Retrieved from the Internet Mar. 7, 2019, <https://www.uniprot.org/uniparc/UPI000 511D809>, Oct. 2014.
[cited by applicant]
Apschner, A., et al., “Pathological mineralization in a zebrafish enpp1 mutant exhibits features of Generalized Arterial Calcification of Infancy (GACI) and Pseudoxanthoma Elasticum (PXE)”, Disease Models & Mechanisms, …
[cited by applicant]
Ayuso, et al., Production, Purification and Characterization of Aden-Associated Vectors, Current Gene Therapy 2010, 10:423-436.
[cited by applicant]
Baheti et al., “Excipients used in lyophilization of small molecules” IPEC-Americas Inc., p. 41-54, Jun. 2010.
[cited by applicant]
Beck et al., “Therapeutic Fc-fusion Proteins and Peptides as Successful Alternatives to Antibodies,” 3:5, 415-416 (2011).
[cited by applicant]
Belisário , et al., “Association between ENPP1 K173Q and stroke in a newborn cohort of 395 Brazilian children with sickle cell anemia”, Blood. 126(10), 2015, 1259-1260.
[cited by applicant]
Belli, et al., “Identification and characterization of a soluble form of the plasma cell membrane glycoprotein PC-1 (5′-nucleotide phosphodiesterase),” European Journal of Biochemistry, 217, 421-428, Feb. 1993.
[cited by applicant]
Benoist, et al., “In vivo sequence requirements of the SV40 early promoter region”, Nature 290, 1981, 304-310.
[cited by applicant]
Bertrand, et al., “Decreased levels of nucleotide pyrophosphatase phosphodiesterase 1 are associated with cartilage calcification in osteoarthritis and trigger osteoarthritic changes in mice”, Annals of the Rheumatic Di…
[cited by applicant]
Blytt, et al., “Assay of Covalent Intermediate of 5′—Nucleotide Phosphodiesterase” Analytical Biochemistry vol. 147, Issue 2, 1985, 517-520.
[cited by applicant]
Boshart, et al., “A Very Strong Enhancer Is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus,” Cell vol. 41, Issue 2, 1985, 521-530.
[cited by applicant]
Braddock, et al., “Protein Engineering and Glycan Optimization Improves Pharmicokinetics of an Enzyme Biologic 10-fold,” FASEB Journal vol. 33, No. Suppl. 1, 2019, p. 801.1 (Abstract).
[cited by applicant]
Buckley , et al., “Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human molecule, amino acid sequence, and chromosomal location”, J Biol Chem. 265(29), Oct. 1990, 17506-17511.
[cited by applicant]
Caballero , et al., “Impaired urinary osteopontin excretion in Npt2a-/- mice”, Am J Physiol Renal Physiol. 312(1), 2017, F77-F83.
[cited by applicant]
Casales, et al., “Development of a new noncytopathic Semliki Forest virus vector providing high expression levels and stability”, Virology 376 (2008) 242-251.
[cited by applicant]
Chamow, S. M. et al., “Immunoadhesins: Principles and Applications,” Trends Biotechnol., 14(2); 52-60 (1996).
[cited by applicant]
Cheung, et al., “Analysis of Inorganic Pyrophosphate at the Picomole Level”, Analytical Biochemistry vol. 83, 1977, 61-63.
[cited by applicant]
“Chronic Renal Failure: From the Perspective of Internal Medicine”, Clinical Imagiology 21(11), 2005, 1142-1149 Partial Translation).
[cited by applicant]
Cimpean, et al., “Substrate-specifying determinants of the nucleotide pyrophosphatases/phosphodiesterases NPP1 and NPP2”, Biochem J. 381(Pt 1) ,2004, 71-77.
[cited by applicant]
Colella, et al., “Emerging Issues in AAV-Mediated In Vivo Gene Therapy”, Molecular Therapy: Methods & Clinical Development vol. 8, 2018, 87-104.
[cited by applicant]
Dabisch-Ruthe, M., et al., “Pyrophosphates as a major inhibitor of matrix calcification in Pseudoxanthoma elasticum,” Journal of Dermatological Science, Elsevier, Amsterdam, NL, vol. 75, No. 2, May 17, 2014, pp. 109-120.
[cited by applicant]
Dabisch-Ruthe, M., et al., “Variants in genes encoding pyrophosphate metabolizing enzymes are associated with Pseudoxanthoma eslasticum,” Clinical Biochemsitry, 2014, vol. 47, No. 15, pp. 60-67.
[cited by applicant]
Dall'Acqua, et al. “Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.” The Journal of Immunology 169.9 (2002): 5171-5180.
[cited by applicant]
Dasgupta , et al., “Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis”, J Am Sac Nephrol. 25(10), 2014, 2366-2375.
[cited by applicant]
Di Lullo et al. 2015; Left ventricular hypertrophy in chronic kidney disease patients: From pathophysiology to treatment. CardioRenal Medicine. 5: 254-266.
[cited by applicant]
Dimatteo, et al., “Role of somatomedin-B-like domains on ENPP1 inhibition of insulin signaling,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research vol. 1833, No. 3, 2012, pp. 552-558.
[cited by applicant]
Dohler, et al. “Crystal structure and substrate binding mode of ectonucleotide phosphodiesterase/pyrophosphatase-3 (NPP3),” Scientific reports 8.1 (2018): 1-13.
[cited by applicant]
Eller, et al. “Impact of ENPP1 genotype on arterial calcification in patients with end-stage renal failure”, Nephrol Dial Transplant. 23(1), 2008, 321-327.
[cited by applicant]
Fang, L., et al., “Pdgf C Is A Selective alpha Platelet-Derived Growth Factor Receptor Agonist That Is Highly Expressed in Platelet alpha Granules and Vascular Smooth Muscle,” Arterioscler. Thromb. Vasc. Biol. 24, 2004,…
[cited by applicant]
Flanagan , et al., “Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia”, Blood. 121(16), 2013, 3237-3245.
[cited by applicant]
Flanagan, et al., “Soluble Fc fusion proteins for biomedical research,” in Monoclonal Antibodies, Methods and Protocols, et. By Albitar, Methods in Molecular Biology, (2007) vol. 378, 33-52.
[cited by applicant]
Fleisch , et al., “Inhibitors and promoters of stone formation”, Kidney Int. 13(5), 1978, 361-371.
[cited by applicant]
Frolov, et al., “Selection of RNA Replicons Capable of Persistent Noncytopathic Replication in Mammalian Cells”, Journal of Virology, 1999, 3854-3865.
[cited by applicant]
Gijsbers , et al., “Functional characterization of the non-catalytic ectodomains of the nucleotide pyrophosphatase/phosphodiesterase NPP1”, Biochem J. 371(Pt 2), Apr. 15, 2003, 321-330.
[cited by applicant]
Gijsbers , et al., “The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site,” FEBS Letters, 538:60-64 (2003).
[cited by applicant]
Gijsbers, et al., “Structural and Catalytic Similarities between Nucleotide Pyrophosphatases/Phosphodiesterases and Alkaline Phosphatases”, The Journal of Biological Chemistry vol. 276, No. 2, 2001, 1361-1368.
[cited by applicant]
Goding , et al., “Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family”, Biochim Biophys Acta. 1638(1), 2003, 1-19.
[cited by applicant]
Goldman, et al., Hydrolysis of diadenosine 5′,5″-P′,PΔ-triphosphate (Ap3A) by porcine aortic endothelial cells, Circ Res. 59(3) , 1986 , 362-366.
[cited by applicant]
Green, et al., “Analysis of human tonsil and cancer DNAs and RNAs for DNA sequences of group C (serotypes 1, 2, 5, and 6) human adenoviruses”, Proc. Natl. Acad. Sci. USA 1979, vol. 76, No. 12, 6606-6610.
[cited by applicant]
Guan, et al., “Peptide-Targeted Polyglutamic Acid Doxorubicin Conjugates for the Treatment of αvB6-Positive Cancers,” Bioconjug Chem., 19:1813-1821 (2008).
[cited by applicant]
Guanabens, N., et al., “Calcific Periarthritis as the Only Clinical Manifestation of Hypophosphatasia in Middle-Aged Sisters,” Journal of Bone ande Mineral Research, 2014, vol. 29, No. 4, pp. 929-934.
[cited by applicant]
Guo et al., “Clinical outcomes of various continued antiplatelet therapies in patients who were administered DAPT following the implantation of drug-eluting stents and developed gastrointestinal hemorrhage”, Exp Ther Me…
[cited by applicant]
Halbert, et al., “AAV-Mediated Gene Transfer to Mouse Lungs”, Methods in Molecular Biology, vol. 246, 2004, 201-212.
[cited by applicant]
Huang, “Receptor-Fc Fusion Therapeutics, traps, and MIMETIBODY Technology,” Current Opinion in Biotechnology, 20:692-699 (2009).
[cited by applicant]
Pakula et al., Genetic analysis of protein stability and function, Ann. Rev. Genet., 23: 289-310 (Dec. 1989).
[cited by applicant]
Keskin et al., A new, structurally nonredundant, diverse data set of protein-protein interfaces and its implications, Protein Sci., 13(4): 1043-1055 (Apr. 2004).
[cited by applicant]